New drug targets rare BRAF mutations in advanced cancers
NCT ID NCT06400225
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 29 times
Summary
This study tests a drug called ulixertinib in people with advanced cancers that have certain changes in the BRAF gene (mutations or fusions). The drug works by blocking signals that tell cancer cells to grow. About 35 adults with solid tumors, lymphoma, or multiple myeloma that haven't responded to other treatments will take part. The main goal is to see if the drug can shrink tumors or stop them from growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.